CASTLE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CASTLE BIOSCIENCES, INC. (CSTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $1.20M, a 29.41% decline from fiscal 2024.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.70M, a 30.77% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.30M, a 64.86% decline from fiscal 2022.
- CASTLE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $3.70M, a 86.39% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.20M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.70M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $1.30M 10-K · filed 2026-02-26 | $1.28M 10-K · filed 2024-02-28 |
| 2022-12-31 | $3.70M 10-K · filed 2025-02-27 | $3.75M 10-K · filed 2023-02-28 |
| 2021-12-31 | $27.19M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $18.38M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $5.15M 10-K · filed 2021-03-11 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |